Ray Therapeutics

Private

Clinical-stage biotechnology company developing optogenetic gene therapies to restore vision in patients with blinding retinal diseases. Delivers bioengineered, highly light-sensitive proteins to targeted retinal cells via a single intravitreal injection. Lead program RTx-015 targets retinitis pigmentosa with FDA RMAT designation. Approach is mutation-agnostic, working across many genetic causes of blindness.

Founders Paul Bresge, Sean Ainsworth

CEO Paul Bresge

Company

Founded

2021

Headquarters

Berkeley, United States

Financials

Total Funding

$231M

Sectors

Healthtech Biotech

raytherapeutics.com

Funding History

3 rounds

Series B Apr 21, 2026

$125M

Janus Henderson Investors (Lead) Adage Capital Management Franklin Templeton Invus Marshall Wace 4BIO Capital Deerfield Management Novo Holdings Norwest Venture Partners Platanus

Series A May 16, 2023

$100M

Novo Holdings (Lead) 4BIO Capital Deerfield Management Norwest Venture Partners Platanus MRL Ventures Fund

Seed Jan 4, 2022

$6M

4BIO Capital (Lead)

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.